Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5615_Библиотеки_им_академика_М_И_Перельмана.pdf
X
- •PEGylated Nanocarriers in Medicine and Pharmacy
- •Preface
- •Contents
- •Editors and Contributors
- •About the Editors
- •Contributors
- •1.1.3.1 Passive Targeting Agent
- •1.1.3.2 Solubility Enhancers
- •1. PEGylated Pharmaceutical Nanocarriers
- •1.1 PEGylation
- •1.1.1 PEG Characteristics
- •1.2 PEGylation Determination
- •1.2.2.1 Thermal Gravimetric Analysis (TGA)
- •1.2.2.2 Nuclear Magnetic Resonance (NMR)
- •1.2.2.4 X-Ray Photoelectron Spectroscopy
- •1.3.1 Nanoparticulate System
- •1.3.1.1 Solid Lipid Nanoparticles
- •1.3.1.2 Nanostructured Lipid Carriers (NLCs)
- •1.3.1.3 Polymeric Nanoparticles
- •1.3.2 Metal Nanoparticles
- •1.3.2.1 Silver Nanoparticles
- •1.3.2.2 Gold Nanoparticles
- •1.3.2.3 Titanium Dioxide Nanoparticles
- •1.3.2.4 Copper Nanoparticles
- •1.3.3 Vesicular Systems
- •1.3.3.1 Liposomes
- •1.3.3.2 Niosomes
- •1.3.3.3 Ethosomes
- •1.4.1 Cancer
- •1.4.2 Gene Delivery
- •1.4.3 Diagnostics Imaging
- •1.4.4 Vaccines
- •1.4.5 Rheumatoid Arthritis
- •1.4.6 Hemophilia
- •1.4.7 Pain Therapy
- •1.4.8 Diabetes
- •1.4.9 Others
- •1.6 Conclusion
- •References
- •2.1 Introduction
- •Nanoprecipitation (Solvent Diffusion)
- •Emulsification (Solvent Evaporation or Nanoemulsion)
- •Physical Adsorption Strategy
- •2.2.2.1 Pre-Insertion PEGylation
- •2.2.2.2 Post-Insertion PEGylation
- •2.3.1 Indirect Assessment (Qualitative Assessment)
- •2.3.1.1 Particle Size
- •2.3.1.2 Zeta Potential
- •2.3.1.3 Surface Hydrophilicity
- •2.3.1.4 Microscopic Techniques
- •2.3.1.5 Fourier Transform-Infrared Spectroscopy (FT-IR)
- •2.3.2 Direct Assessment (Quantitative Assessment)
- •2.3.2.1 Colorimetric Methods
- •2.3.2.2 Chromatographic Methods
- •2.3.2.4 Nuclear Magnetic Resonance (NMR)
- •2.3.2.5 X-Ray Photoelectron Spectroscopy (XPS)
- •References
- •3.1 Introduction
- •3.2 Characterization Techniques
- •3.3 Infrared Spectroscopy
- •3.4 Raman Spectroscopy
- •3.5 X-Ray Photoelectron Spectroscopy
- •3.6 Nuclear Magnetic Resonance
- •3.7 Energy-Dispersive X-Ray Spectroscopy
- •3.8 Mass Spectroscopy (MS)
- •3.9 Thermogravimetric Analysis
- •3.10 Differential Scanning Calorimetry
- •3.11 Atomic Force Microscopy
- •3.12 Scanning Electron Microscopy
- •3.13 Transmission Electron Microscopy
- •3.14 Conclusion
- •References
- •4.1 Introduction
- •4.3.1 Nanoparticles PEGylation
- •4.3.2 Polyplexes (PP) PEGylation
- •4.5.1 Systemic Drug Delivery
- •4.5.2 Nonsystemic Drug Delivery
- •4.5.2.3 PEGylated Intravaginal Nanocarriers
- •4.5.2.6 Vaccines Entrapped PEGylated Nanocarriers
- •4.6.2 PEG Molecular Weight (MW)
- •4.7 PEGylated Nanocarriers Products
- •4.8.3 Disadvantageous Physicochemical Properties
- •4.8.5 Limited RES Evasion Capacity
- •4.9 Conclusion
- •References
- •5.1 Introduction
- •5.1.2 PEG Solubility Characteristics
- •5.2 Water-Soluble PEGylated Small Molecule Drugs
- •5.3 Soluble PEGylated Proteins/Enzymes
- •5.3.2 Organic Solvent–Soluble PEGylated Proteins/Enzymes
- •5.4 Water-Soluble PEGylated Drug Nanocarriers
- •5.4.1 Water-Soluble PEGylated Silicon Nanocarriers
- •5.4.2 Water-Soluble PEGylated Carbon Nanotubes
- •5.4.4 Water-Soluble PEGylated Dendrimers
- •5.4.5 Water-Soluble PEGylated Polymeric Micelles
- •5.5 Hydrated or Hydrophilic PEGylated Drug Nanocarriers
- •5.5.1 Hydrated PEGylated Lipid Nanocarriers
- •5.5.2 Hydrophilic PEG-Coated Zein Nanocarriers
- •References
- •5.6.4.1 PEG Chain Length/Molecular Weight
- •6.1 Introduction
- •Increased Solubility
- •Improved Stability
- •Reduced Immunogenicity
- •Enhanced Circulation Time
- •Heterogeneity
- •6.3.1 Enhancing Immune Responses
- •6.3.2 Suppressing Immune Responses
- •6.3.3 Immune Evasion
- •6.4.1 Strategies to Overcome Immunological Barriers
- •6.4.1.1 PEGylation
- •6.4.1.2 Cell Membranes
- •6.4.1.3 Carbohydrates
- •6.4.1.4 Proteins
- •6.6.1 Cancer Therapy
- •6.6.2 Gene Therapy
- •6.6.3 Immunotherapy
- •6.6.4 Central Nervous System (CNS) Drug Delivery
- •6.6.5 Pulmonary Drug Delivery
- •6.6.6 Ocular Drug Delivery
- •6.6.7 Cardiovascular (CVS) Drug Delivery
- •6.8 Conclusion
- •References
- •7.1 Introduction
- •7.3 Nanocarrier-Based Targeted Drug Delivery
- •7.4.1 Covalent Approach
- •7.4.2 Non-covalent Approach
- •7.4.2.1 PEGylation Via Monovalent Interactions
- •High-Affinity Host-Guest Interactions
- •7.4.2.2 PEGylation Via Multivalent Interactions
- •PEGylated Block Copolymers
- •PEGylated Graft Copolymers
- •Polyelectrolyte Complex-Based Systems
- •Non-ionic Interaction-Based Systems
- •PEGylated Dendritic Copolymers
- •PEGylated Copolymers Utilizing Mobile Side Groups
- •7.5 Various Targeting Strategies
- •7.5.1 Active Targeting
- •7.5.2 Passive Targeting
- •7.5.2.1 PEG Dilemma
- •7.7.1 Brain Disorders
- •7.7.2 Pulmonary Disorders
- •7.7.3 Cancer
- •7.7.4 Inflammatory Disorders
- •7.7.5 Bone Disorders
- •7.7.6 Blood Disorders
- •7.8 Stimuli-Sensitive Nanocarriers
- •7.8.1 External-Responsive Nanocarriers
- •7.8.1.1 Ultrasound-Responsive PEGylated Nanocarriers
- •7.8.1.2 Thermal-Responsive PEGylated Nanocarriers
- •7.8.1.3 Magnetic Responsive PEGylated Nanocarriers
- •7.8.2 Internal-Responsive Nanocarriers
- •7.8.2.1 pH-Responsive Systems
- •7.8.2.2 Redox-Responsive Systems
- •7.8.2.3 Enzyme-Responsive Systems
- •7.8.2.4 Hypoxia-Responsive Systems
- •7.8.3 Multimodal Responsive Nanocarriers
- •7.9 Conclusion
- •References
- •8.1 Introduction
- •8.3.1 PEGylated Liposome
- •8.3.2 PEGylated Micelles
- •8.3.3 PEGylated Nanogels
- •8.3.4 PEGylated Inorganic Nanoparticles
- •8.3.5 PEGylated Polymeric Nanoparticles
- •8.4.1 Cancer
- •8.4.1.1 Breast Cancer
- •8.4.1.2 Lung Cancer
- •8.4.1.3 Colon Cancer
- •8.4.1.4 Brain Cancer
- •8.4.2 Autoimmune Diseases
- •8.4.3 Inflammatory Disorders
- •8.4.4 Cardiovascular Diseases
- •8.4.5 Ocular Diseases
- •8.5 Conclusion
- •References
- •9.1 Introduction
- •9.4.1.1 Amino Acid Modifications
- •9.4.1.3 Cysteine Thiol Residue Conjugation
- •9.4.2 Releasable PEGs
- •9.7.1.1 Cationic Lipid Toxicology
- •9.8 RNA Lipid Nanoparticle
- •9.13 Conclusion
- •References
- •10.2.1 PEGylated Nanocarriers
- •10.2.1.1 Polymeric NPs
- •10.2.1.2 Liposomes
- •10.2.1.3 Dendrimers
- •10.2.1.4 Polymeric Micelles
- •10.6 Conclusion
- •References
- •11.1 Introduction
- •11.1.2 Factors Influencing PPDs’ Short-Term Efficiency
- •11.2 What Is PEGylation?
- •11.3.1 Random PEGylation
- •11.3.2 Site-Specific PEGylation
- •11.3.2.1 Amine Conjugation
- •11.3.2.2 Cysteine Conjugation
- •11.4.1 Binding Affinity
- •11.4.2 Altered Biological Activity
- •11.4.3 Physicochemical Modifications
- •11.4.4 PEG Size
- •11.4.5 PEG Structure
- •11.6 PK Profiling
- •11.9 FDA-Approved PEGylated Products
- •11.11 Conclusion
- •References
- •12.1 Introduction
- •12.1.2 Current Market Scenario
- •12.2.1 PEGylated Iron Oxide Nanoparticles
- •References
- •13.1 Introduction
- •13.2.1 PEGylated Lipid-Based NPs
- •13.2.2 PEGylated Polymeric Nanoparticles
- •13.2.3 PEGylated Metal-Based Nanoparticles
- •13.2.4 Multifunctional PEGylated Nanocarriers
- •13.2.5 Targeted PEGylated Nanocarriers
- •13.3.1 Surface Modification Chemistry
- •13.3.2 Polymer Chemistry
- •13.3.4 Characterization Techniques
- •13.4.1 Longer Circulation Time
- •13.4.2 Enhanced Cellular Uptake
- •13.4.3 Controlled Drug Release
- •13.5.1 Cancer Theragnostic
- •13.5.2 Cardiovascular Theragnostic
- •13.7.2 Prolonged Circulation Time
- •13.7.3 Improved Drug Delivery
- •13.7.4 Diagnostic Functionality
- •13.8 Technical Challenges
- •13.8.4 Limited Clinical Validation
- •13.10 Conclusion
- •References
- •14.1 Introduction
- •14.2 Reversible PEGylation Strategies
- •14.2.1 Reversible PEGylation Chemistry
- •14.2.2.1 Aromatic Linkers
- •14.2.2.2 Aliphatic Linkers
- •14.2.3 Cleavage Linkers
- •14.2.3.1 Hydrolyzable Linkers
- •14.2.3.2 Enzymatically Cleavable Linkers
- •14.2.4 pH-Responsive PEGylation
- •14.2.4.1 Proteasome Inhibitor MG132
- •14.2.5 Temperature-Responsive PEGylation
- •14.2.6 Light-Responsive PEGylation
- •14.3.1 Analytical Techniques
- •Zeta Potential
- •Hydrophobic Interaction Chromatography (HIC)
- •Near Infrared (NIR) Spectroscopy
- •Fourier Transform-Infrared Spectroscopy (FT-IR)
- •13C-NMR
- •Mass Spectrometry
- •High-Performance Liquid Chromatography (HPLC)
- •Calorimetry
- •X-Ray Photoelectron Spectroscopy (XPS)
- •Nuclear Magnetic Resonance (NMR)
- •TGA-DSC
- •14.3.2.1 Protein Adsorption
- •14.3.2.2 Cellular Association
- •14.3.2.5 Bioactivity Assay
- •14.3.2.6 Enzyme-Linked Immunosorbent Assay (ELISA)
- •14.3.2.7 Sandwich ELISA
- •14.3.2.8 Anti-PEG ELISA
- •14.3.3.1 In Vivo Blood Circulation Half-Life
- •14.3.3.2 Radiolabeling
- •14.4.1 Therapeutic Applications
- •14.4.1.1 Anticancer Activity
- •14.4.1.2 Antibiotic Administration
- •14.4.1.3 Enzyme-Replacement Therapy
- •14.4.1.4 Red Blood Cell Substitution
- •14.4.1.5 Oxygen Toxicity Diseases
- •14.4.2 Pharmaceutical Applications
- •14.4.2.1 PEGylated Liposomes
- •14.4.2.2 PEGylated Proteins
- •14.4.2.3 Targeted Delivery
- •14.5.1 Design Complexity
- •14.5.3 Biological Environment Stability
- •14.5.4 Trigger Selection
- •14.5.5 Immunogenicity
- •14.5.6 Scale-up Difficulties
- •14.5.8 Cost
- •14.6 Conclusion
- •References
- •15. Stimuli-Responsive PEGylated Nanocarriers
- •15.1 Introduction
- •15.2 External Stimuli-Responsive Systems
- •15.2.1 Thermoresponsive Systems
- •15.2.2 Magnetically Responsive Systems
- •15.2.3 Ultrasound-Triggered Drug Delivery
- •15.2.4 Light-Triggered Drug Delivery
- •15.2.5 Electroresponsive Systems
- •15.3 Internal Stimuli-Responsive Systems
- •15.3.1 pH-Responsive Systems
- •15.3.2 Redox-Responsive Systems
- •15.3.3 Enzyme-Responsive Systems
- •15.3.4 Self-Regulated Systems
- •15.4.3 Multistimuli Responsive Systems
- •15.7 Conclusion
- •References
- •16.1 Introduction
- •16.3 PEGylated Products
- •16.3.1 PEGylated Liposomes
- •16.3.2 PEGylated G-CSF
- •16.3.3 PEGylated Proteins
- •16.3.4 PEGylated Nanoparticles
- •16.5.1 Poly(Zwitterions)
- •16.5.2 Poly(Glycerols)
- •16.5.3 Poly(Amino Acids)
- •16.5.4 Poly(Oxazolines)
- •16.5.6 Poly(Vinylpyrrolidones)
- •16.5.8 Polypeptides
- •16.5.9 Carbohydrate-Based Systems
- •16.5.10 Hydrophilic Polymers
- •16.5.11 Non-PEGylated Nanoparticles
- •16.6 Future Prospects
- •16.7 Conclusion
- •References

RakeshKumarTekade·
NarendraKumarJainEditors
PEGylated
Nanocarriers
in Medicine
and Pharmacy

PEGylated Nanocarriers in Medicine
and Pharmacy

Rakesh Kumar Tekade
Narendra Kumar Jain
Editors
PEGylated Nanocarriers in Medicine and Pharmacy

Editors
Rakesh Kumar Tekade
National Institute of Pharmaceutical
Education and Research (NIPER)
Ahmedabad, An Institute of National
Importance, Government of India,
Department of Pharmaceuticals, Ministry of
Chemicals and Fertilizers, Palaj, Opp. Air
force station, Gandhinagar, Gujarat, India
Narendra Kumar Jain
Department of Pharmaceutical Sciences
Dr. Hari Singh Gour University
Sagar, Madhya Pradesh, India
ISBN 978-981-97-7315-2 ISBN 978-981-97-7316-9 (eBook)
https://doi.org/10.1007/978-981-97-7316-9
© The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Singapore
Pte Ltd. 2024
This work is subject to copyright. All rights are solely and exclusively licensed by the Publisher, whether
the whole or part of the material is concerned, specically the rights of translation, reprinting, reuse of
illustrations, recitation, broadcasting, reproduction on microlms or in any other physical way, and
transmission or information storage and retrieval, electronic adaptation, computer software, or by similar
or dissimilar methodology now known or hereafter developed.
The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication
does not imply, even in the absence of a specic statement, that such names are exempt from the relevant
protective laws and regulations and therefore free for general use.
The publisher, the authors and the editors are safe to assume that the advice and information in this book
are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the
editors give a warranty, expressed or implied, with respect to the material contained herein or for any
errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional
claims in published maps and institutional afliations.
This Springer imprint is published by the registered company Springer Nature Singapore Pte Ltd.
The registered company address is: 152 Beach Road, #21-01/04 Gateway East, Singapore 189721,
Singapore
If disposing of this product, please recycle the paper.

Preface
The editors welcome the readers into the fascinating world of PEGylation through
this unique book, which embarks on a voyage via an inclusive landscape of historical perspectives, groundbreaking discoveries, and technologies in medicine and the
healthcare sector. Notably, since the advent of this technology in 1970, it seemingly
offers remarkable properties to therapeutic molecules such as proteins, peptides,
drugs, drug carriers, etc., through the properties bestowed upon them. PEGylation
technology undeniably emerged as the show’s topper; the rest is history. This book
answers all basic concepts and scientic queries, beginning with fundamental to
contemporary advancements in the eld.
With this book, readers will be able to understand how PEGylation technology
can enhance safety as well as therapeutic potential of drugs. It will shed light on
how this technology can transform difcult-to-deliver therapeutic moiety into an
extraordinary one. PEGylation enhances the solubility of a drug and makes it more
water-friendly. PEG layering grants immunity from biological degradation and lowers immune recognition. It precisely extends the biological half-life of an agent
within the body, as if it offers a VIP tag to it by allowing it to stay longer in the
physiological compartment. It is projected that the readers will be exceptionally
amazed by the versatility of PEGylation technology as they progress to read the
book page-by-page. From solubilization, drug delivery, and targeting avenues to
diagnosis and theragnosis, it has an impactful resonance and echoes across all the
elds of healthcare and medicine. The editors of this book invite readers to embark
on an exciting journey to explore the innite potential of PEGylation, a simple yet
immensely versatile technology.
Ahmedabad, Gujarat, India RakeshKumarTekade
Sagar, Madhya Pradesh, India NarendraKumarJain
v

Contents
1 PEGylated Pharmaceutical Nanocarriers . . . . . . . . . . . . . . . . . . . . . . . 1
Prashant Pingale, Sakshi Wani, Sahebrao Boraste, and
Amarjitsing Rajput
2 Methods and Protocols for the Synthesis of PEGylated
Pharmaceutical Nanocarriers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
Ala’ Adnan Ali, Rakesh Kumar Tekade, and Randa S. H. Mansour
3 Topographic Properties of PEGylated Nanocarriers . . . . . . . . . . . . . . . 69
Aprameya Ganesh Prasad, Shivam Otavi, Mahima Mishra, and
Rakesh Kumar Tekade
4 PEGylated Nanocarriers for Drug Delivery Applications . . . . . . . . . . . 107
Salome A. Chime and Mumuni A. Momoh
5 PEGylated Nanocarriers for Solubilization . . . . . . . . . . . . . . . . . . . . . . 137
Randa S. H. Mansour, Rakesh Kumar Tekade, and Ala’ Adnan Ali
6 PEGylation as a Tool to Alter Immunological Properties of
Nanocarriers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 171
Akhilesh Tiwari, Sourajyoti Goswami, Megha Joshi, Sanyam
Gandhi, Pranay Soni, Muktika Tekade, Shubham Ramdas Mule, and
Rakesh Kumar Tekade
7 PEGylated Nanocarrier as a Promising Tool for Site-Specific
Delivery of Therapeutics. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 195
Sweta Acharya, Niyati Lad, Aniket Navale, Simranjit Kaur,
Aprameya Ganesh Prasad, and Rakesh Kumar Tekade
8 PEGylated Nanocarriers for Gene Therapy . . . . . . . . . . . . . . . . . . . . . . 239
Lopamudra Mishra, Lakshmi Kumari, Yash Sharma, Kanak Chahar,
Satyam Khare, Preeti Patel, Dilpreet Singh, and Balak Das Kurmi
9 PEGylated Nanocarrier System for Nucleic Acid Delivery . . . . . . . . . . 275
Akhilesh Tiwari, Sreeharsha Nagaraja, Rakesh Sahu, and
Muktika Tekade
vii

viii
Contents
10 PEGylated Nanocarriers for Protein and Peptide Delivery . . . . . . . . . 295
Tejas Girish Agnihotri, Vasu Peddinti, Shyam Sudhakar Gomte,
Biswajit Rout, and Aakanchha Jain
11 PEGylation of Therapeutic Proteins and Peptides . . . . . . . . . . . . . . . . 317
Natasha Akojwar, Ankit Mishra, Pranali Mishra, Muktika Tekade,
Shubham Ramdas Mule, and Rakesh Kumar Tekade
12 PEGylated Nanocarriers for Diagnostic Applications . . . . . . . . . . . . . . 345
Naveen Gupta, Ankit Mishra, Pran Kishore Deb, and
Muktika Tekade
13 Multifunctional PEGylated Nanoparticles in Theragnosis . . . . . . . . . . 367
Akhilesh Tiwari, Muktika Tekade, Shubham Ramdas Mule, Girish
Meravanige Basavarajappa, and Rakesh Kumar Tekade
14 Reversible PEGylation of Nanocarriers . . . . . . . . . . . . . . . . . . . . . . . . . 385
Mahima Mishra, Sweety Shah, Gagandeep Kaur, Aniket Navale,
Heet Jani, Vaishnavi Chinkure, and Rakesh Kumar Tekade
15 Stimuli-Responsive PEGylated Nanocarriers . . . . . . . . . . . . . . . . . . . . 423
Samah Hamed Almurisi, Prasanthi Sri Nagindera Rao, and
Thiagarajan Madheswaran
16 Beyond PEGylation “PEGylation and its Alternatives” . . . . . . . . . . . . 455
Sehasree Mohanta, Anuja Muley, Mansi Upadhyay, Dwiptesha
Dahake, Muktika Tekade, Aprameya Ganesh Prasad, and Rakesh
Kumar Tekade
17 Current Clinical, Regulatory, and Patent Aspects of PEGylated
Nanoproducts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 495
Sombir Saharan, Sajidul Hoque, Piyush Neware, V. Ravichandiran,
and Vinod Gaikwad
18 Therapeutic and Pharmaceutical Applications of PEGylated
Nano-Carriers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 555
Raheleh Shakeri, Seyedeh Zohreh Mirjalili, Ceyda Oksel Karakus,
and Maliheh Safavi

Editors and Contributors
About the Editors
Rakesh Kumar Tekade, currently working as an
Associate Professor at NIPER-Ahmedabad, is an academic researcher with more than 15years of teaching
and research experience. Before joining NIPERAhmedabad, he served as a Faculty at the Indian
Institute of Technology (IIT), Jammu and at
International Medical University, Malaysia, Kuala
Lumpur. His current research involves developing tto-purpose, translational, and novel targeted specic
nano-biomaterials for biomedical applications. He has
co-authored more than 350 publications (>16500 citations; h-index: 65). He has edited 10 reference books
with Elsevier (as editor-in-chief), 05 invited editorial
articles, and 11 patent applications to his credit. For the
past four consecutive years, he has been listed as one of
the top 2% of researchers in Pharmacy and
Pharmacology by Stanford University, USA.He was a
recipient of several acclaimed awards, including
Commonwealth Fellowships (British Council;
University of Central Lancashire, UK), National
Doctoral Fellowship (AICTE-NDF), Irish Government
Postdoctoral Award (IRISH-PDF), and CSIR Senior
Research Fellowship (CSIR-SRF), India and Junior
Research Fellowship, India (AICTE-JRF), Best
Associate Professor Award 2023, etc. to name the few.
Dr. Tekade underwent two postdoctoral trainings
from The University of Hawaii, USA, and The
University of Texas Southwestern Medical Center,
USA. So far, he has trained 05 postdocs in his lab,
guided 16 Ph.D. (08 completed and 8in progress), and
supervised 75 master’s and biomedical science dissertations. He served/serving as a Principal Investigator for
ix

x
Editors and Contributors
various extramurally funded projects (worth more
than2Crore) funded by DST, ICMR, MOSTI, etc. He
is a recipient of the Pharma Innova Award by Troika
Pharmaceuticals Ltd. for Best Research Mentor and the
Best Thesis Award. Dr. Tekade is a grant reviewer for
the FONDECYT funds (Chile), the National Science
Centre (Poland), the French National Research Agency
(ANR) (France), the Khwarizmi International Award
(KIA) (Iran), and a referee for more than 30 reputed
international journals. Dr. Tekade is an editor-in-chief
of a book series entitled Advances in Pharmaceutical
Product Development and Research Series. https://
www.elsevier.com/catalog/pharma/pharmaceuticalscience/drug- delivery/advances- in- pharmaceutical-
product- development- and- research.
Narendra Kumar Jain is an internationally
renowned academician and researcher and a senior professor in India who superannuated in June 2014 after
rendering more than 40 years of dedicated and distinguished service as a teacher and 25years as full professor. Starting his academic career in 1973, he worked as
Lecturer in Pharmacy, Holkar College, Indore; Reader
in Pharmaceutical Technology; M.S. University,
Baroda; Professor and Principal, College of Pharmacy,
Nasik; Professor and Head, Department of
Pharmaceutical Sciences, Dr. H. S. Gour University,
Sagar; Principal, College of Pharmacy, New Delhi;
Visiting Professor, Dubai Pharmacy College, Dubai
(UAE); and Head, Pharmacy Department, Delhi
University. Subsequent to his superannuation, Prof. Jain
rendered his services as Director, ISF College of
Pharmacy, Moga, Punjab, India, and as Emeritus Fellow
(U.G.C.) at Rajiv Gandhi Technological University,
Bhopal, M.P., India.
Prof. Jain is the author of over two dozen celebrated
books in pharmaceutical sciences including a series on
controlled and novel drug delivery systems and has contributed over 60 chapters in national and international
books. He has to his credit over 500 publications in
reputed pharmaceutical journals and has supervised 55
Ph.D. and 142 M.Pharm. candidates. He has been a
reviewer for several international and national research
journals. Professor Jain has been the recipient of IDMA

Editors and Contributors
xi
Research Award in Industrial Pharmacy in 1990, 1997,
and 2004; Motan Devi Dandiya Award for Best
Publication in Pharmacy in 1999; M.L.Khorana Prize
for Best Research Paper in Pharmaceutics and
Biopharmaceutics published in IJPS in 2003; Prof.
M.L. Khorana Memorial Prize for Best Paper in the
eld of Pharmaceutics and Biopharmaceutics published
in IJPS during the year 2006; “Teacher of the Year
2003” award from the Association of Pharmaceutical
Teachers of India; “Dr. (Mrs.) Manjushree Pal Memorial
Award of the Association of Pharmaceutical Teachers of
India for Best Pharmaceutical Scientist” in 2008;
Schroff Memorial National Award for his outstanding
contributions as an author, academician, and scientist
by the Indian Hospital Pharmacists’ Association in
2008; and Motan Devi Dandiya Biennial Prize in
Pharmacy for Best Publication in 2010.
Contributors
Samah Hamed Almurisi Department of Pharmaceutical Technology, School of
Pharmacy, International Medical University, Bukit Jalil, Kuala Lumpur, Malaysia
Sweta Acharya National Institute of Pharmaceutical Education and Research
(NIPER) Ahmedabad, An Institute of National Importance, Government of India,
Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Palaj, Opp.
Air force station, Gandhinagar, Gujarat, India
Tejas Girish Agnihotri Department of Pharmaceutics, National Institute of
Pharmaceutical Education and Research (NIPER)-Ahmedabad, Gandhinagar,
Gujarat, India
Natasha Akojwar Department of Pharmaceutics, University Department of
Pharmaceutical Sciences, Nagpur University Campus, Nagpur, MS, India
Ala’AdnanAli Faculty of Pharmacy, Philadelphia University, Amman, Jordan
GirishMeravanigeBasavarajappa Department of Biomedical Sciences, College
of Medicine, King Faisal University, Al-Ahsa, Saudi Arabia
Sahebrao Boraste Department of Pharmaceutics, GES’s Sir Dr. M. S. Gosavi
College of Pharmaceutical Education and Research, Nashik, Maharashtra, India
KanakChahar Department of Pharmaceutics, ISF College of Pharmacy, Moga,
Punjab, India
Соседние файлы в папке Библиотека им академика М.И. Перельмана
